# Reed Jobs and Yosemite: Revolutionizing Cancer Treatment Steve Jobs' son is reshaping cancer treatment with biotechnology and AI. - **Source:** [TechCrunch](https://techcrunch.com) - **Published:** 2026-07-12 - **Topic:** [Finance](https://brifing.si/c/finance) - **Original article:** - **On Brifing:** https://brifing.si/s/27e49e7c-08b6-467b-bf41-8d1db5ab1423 ## Introduction Despite being known as Steve Jobs' son, Reed Jobs wants to make his own name in the biotech world. With his venture firm Yosemite, launched in 2023, he aims to revolutionize cancer treatment. The firm transforms early-stage academic research into commercial companies, combining philanthropy and investment capital. ## Yosemite's Mission Yosemite is a venture capital firm focused solely on oncology. It aims to develop new drugs and methods for cancer treatment. Reed Jobs believes the solutions to cancer lie in university labs, not big pharma. That's why the firm supports early-stage projects. ## The Role of AI Artificial intelligence plays a significant role in Yosemite's work. AI accelerates drug discovery and clinical trial design, creating new opportunities in cancer treatment. Reed Jobs notes that AI is advancing faster than expected in biotech, shaping Yosemite's strategy. ## Portfolio Companies Yosemite's portfolio includes promising companies like Azalea, from Jennifer Doudna's lab, and Quarry, co-founded with Craig Crews. Quarry is developing a novel therapy called 'induced proximity,' which brings disease-causing proteins close to the cell's own breakdown system. ## Second Fund Yosemite announced the first close of its second fund, targeting $350 million. A third of the fund will go into companies Yosemite builds itself, while the rest will be used to join other ventures. Additionally, 2.5% of the fund will go into unconditional grants for academic research. ## Appeal to Investors Reed Jobs argues that Yosemite is a pioneer in creating new medical fields compared to other life science VC firms. They've made strides in areas like epigenetic gene editing and safe gene delivery to specific cells, making the firm highly attractive to investors. ## Biotech Market When Yosemite launched in 2023, the biotech sector was still recovering from a post-pandemic slump. But improved interest rates and pharma's acquisition spree, fueled by record cash reserves, have revitalized the industry, benefiting Yosemite's growth. ## NIH Budget Reed Jobs warns against proposed NIH budget cuts. Last year, a 40% cut was rejected, but this year a 12% cut is on the table. Jobs advocates for increasing the NIH budget, as it hasn't grown in a decade and has effectively shrunk due to inflation. ## AI in Healthcare AI is transforming healthcare delivery. For example, AI-powered call centers like 911 triage reduce costs. Reed Jobs points out that American hospitals lag in technology adoption, presenting a huge opportunity for AI to make an impact. ## Patent Cliff Major pharma companies are losing patent protection for blockbuster drugs, creating opportunities for firms like Yosemite. Reed Jobs sees this as a golden era for biotech innovation. ## Personal Motivation Rather than avoiding his father's legacy, Reed Jobs is carving his own path. His goal to revolutionize cancer treatment is not just a job but a passion, driving Yosemite's success. ## Conclusion Reed Jobs and Yosemite aim to rewrite the future of cancer treatment. By merging biotechnology, AI, and philanthropy, they stand out in the industry. If successful, they could change millions of lives. ## Sources covering this story - https://techcrunch.com/2026/07/11/reed-jobs-would-rather-talk-about-curing-cancer-than-his-last-name/ — --- _Summary written by Brifing from the original reporting. Copyright in the original article belongs to its publisher; read the full piece at the link above._